Tarsus Pharmaceuticals, Inc. (TARS) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Tarsus Pharmaceuticals, Inc. (TARS) Bundle
Enhance your investment strategies with the Tarsus Pharmaceuticals, Inc. (TARS) DCF Calculator! Dive into authentic Tarsus financial data, adjust growth projections and expenses, and instantly observe how these alterations affect the intrinsic value of Tarsus Pharmaceuticals, Inc. (TARS).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 57.0 | 25.8 | 17.4 | 13.6 | 10.7 | 8.3 | 6.5 | 5.1 |
| Revenue Growth, % | 0 | 0 | 0 | -54.73 | -32.42 | -21.79 | -21.79 | -21.79 | -21.79 | -21.79 |
| EBITDA | -4.6 | -26.6 | -13.2 | -59.1 | -131.7 | -.6 | -.5 | -.4 | -.3 | -.2 |
| EBITDA, % | 100 | 100 | -23.09 | -228.95 | -754.69 | -4.62 | -4.62 | -4.62 | -4.62 | -4.62 |
| Depreciation | .1 | .2 | .6 | .8 | .9 | 5.7 | 4.5 | 3.5 | 2.7 | 2.1 |
| Depreciation, % | 100 | 100 | 1.06 | 3.06 | 5.03 | 41.83 | 41.83 | 41.83 | 41.83 | 41.83 |
| EBIT | -4.6 | -26.8 | -13.8 | -59.9 | -132.5 | -.7 | -.5 | -.4 | -.3 | -.2 |
| EBIT, % | 100 | 100 | -24.15 | -232.01 | -759.71 | -4.83 | -4.83 | -4.83 | -4.83 | -4.83 |
| Total Cash | 58.0 | 168.1 | 171.8 | 217.0 | 227.4 | 13.6 | 10.7 | 8.3 | 6.5 | 5.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .1 | 3.6 | 17.7 | 8.6 | 6.7 | 5.2 | 4.1 | 3.2 |
| Account Receivables, % | 100 | 100 | 0.16133 | 13.88 | 101.53 | 62.81 | 62.81 | 62.81 | 62.81 | 62.81 |
| Inventories | .0 | .0 | .0 | 4.8 | 3.1 | 6.4 | 5.0 | 3.9 | 3.1 | 2.4 |
| Inventories, % | 100 | 100 | 0 | 18.45 | 17.81 | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 |
| Accounts Payable | .5 | 2.2 | 2.9 | 5.5 | 18.1 | 8.9 | 7.0 | 5.4 | 4.3 | 3.3 |
| Accounts Payable, % | 100 | 100 | 5.01 | 21.3 | 104.02 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 |
| Capital Expenditure | -.2 | -.5 | -.6 | -.5 | -1.5 | -.3 | -.2 | -.2 | -.2 | -.1 |
| Capital Expenditure, % | 100 | 100 | -1.03 | -1.96 | -8.61 | -2.32 | -2.32 | -2.32 | -2.32 | -2.32 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.6 | -26.8 | -13.8 | -59.9 | -132.5 | -.7 | -.5 | -.4 | -.3 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.3 | -25.2 | -13.3 | -65.2 | -133.0 | 1.3 | 5.0 | 3.9 | 3.1 | 2.4 |
| WACC, % | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 12.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 34 | |||||||||
| Present Terminal Value | 22 | |||||||||
| Enterprise Value | 34 | |||||||||
| Net Debt | -193 | |||||||||
| Equity Value | 227 | |||||||||
| Diluted Shares Outstanding, MM | 29 | |||||||||
| Equity Value Per Share | 7.73 |
What You Will Receive
- Adjustable Forecast Parameters: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Current Market Data: Tarsus Pharmaceuticals, Inc. (TARS) financial information pre-loaded to facilitate your analysis.
- Instant DCF Calculations: The template automatically computes Net Present Value (NPV) and intrinsic value for your convenience.
- Tailored and Professional: A sleek Excel model that conforms to your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life TARS Financials: Pre-filled historical and projected data for Tarsus Pharmaceuticals, Inc. (TARS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Tarsus’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Tarsus’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based TARS DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional variables.
- Instant Calculations: The model will automatically refresh Tarsus Pharmaceuticals' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial analysis.
Why Choose This Calculator for Tarsus Pharmaceuticals, Inc. (TARS)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Adjust assumptions effortlessly to suit your financial analysis.
- Real-Time Feedback: Witness immediate changes in Tarsus’ valuation as you tweak the parameters.
- Preloaded Data: Comes equipped with Tarsus’ actual financial statistics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Pharmaceutical Students: Explore drug development processes and apply theoretical knowledge with real-world examples.
- Researchers: Integrate advanced models into your studies or clinical trials.
- Investors: Evaluate your investment strategies and analyze market performance for Tarsus Pharmaceuticals, Inc. (TARS).
- Market Analysts: Enhance your analysis with a ready-to-use, adaptable financial model.
- Healthcare Professionals: Understand how biopharmaceutical companies like Tarsus are assessed in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Tarsus Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Tarsus Pharmaceuticals, Inc. (TARS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.